Oslo, 14 May 2025: The annual general meeting of Oncoinvent ASA was held today, on 14 May 2025, as a digital meeting through Microsoft Teams. All proposals on the agenda were adopted in accordance with the board of directors’ proposals and the proposals from the nomination committee.
The minutes of the annual general meeting are attached hereto and are also available on the company’s website www.oncoinvent.com/investors/general-meetings.
Oncoinvent ASA has today published the annual report for 2024. The annual report is attached and is also available on the Company’s website, www.oncoinvent.com.
A live streamed of company update in English. The live webcast will be available for everyone to join and there will be a Q&A sesion at the end of the company update. Please join by using the follwoing link (Teams): Oncoinvent ASA: Company update Q1 – 2025
In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a
Live streamed of quarterly presentation in English on Wednesday 30th of April at 11.00 AM CEST. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.
Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial was closed for recruitment at the end of 2023 and patients are currently in long-term follow-up.
Management will be presenting Oncoinvent at the Anglo Nordic Life Science Conference in London.
Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the safety data from the patients in the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer has been reviewed by the company and study investigators. No safety concerns were identified, and based on this review, the company is pleased to confirm that the randomised part of the trial is now initiated, with the first patient successfully enrolled.
Primary insider Anne Cecile Alvik, Head of QA and Board member (employee representative) of Oncoinvent ASA, has 5. March 2025 acquired 8 500 shares in Oncoinvent ASA at an average price of NOK 1,694 per share. Following this transaction, Anne Cecilie owns 13 200 shares in Oncoinvent ASA.
Oncoinvent ASA (OSE: ONCIN) a clinical stage 2 radiopharmaceutical company developing novel radiopharmaceutical therapies against cancer, announces its fourth quarter 2024 results today
Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer.
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.